(Tiper Stock Exchange) – Kolinpharmaa company operating in the nutraceutical sector and listed on the Euronext Growth Milan market, closed the first semester 2023 with a finished product turnover equal to 6.7 million euros, with an increase of approximately 17.3% compared to 5.7 million in the first half of 2022 and 0.2 million euros in sales of raw materials.
The growth trend continues medical prescriptions which in the second quarter of 2023 stood at 213,309, up by 7.51% in terms of volumes compared to 198,416 in the second quarter of 2022 and up by 6.64% in terms of values compared to the same period of the previous year.
As at 30 June 2023 the number of Scientific medical informants (IMS) is equal to 71, compared to 79 in the previous quarter and 89 as at 30 June 2022.